Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies
Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.
Pharma & Biotech
Features & Analysis
Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.
Pharma & Biotech
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.